



May 10, 2024
JCR Pharmaceuticals Co., Ltd.

Translation

Notice of Distribution of Retained Earnings

May 10, 2024 -- JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; “JCR”) announced that its Board of Directors resolved at a meeting today to distribute retained earnings (term-end dividend) with the record date being March 31, 2024.

1. Details of dividends

	Amount decided	Latest forecast for dividend (Released on May 11, 2023)	Actual result for previous fiscal year (ended March 31, 2023)
Record date	March 31, 2024	March 31, 2024	March 31, 2023
Dividends per share	10.00 yen	10.00 yen	10.00 yen
Total amount of dividends	1,251 million yen	-	1,251 million yen
Effective date	June 27, 2024	-	June 22, 2023
Dividend resource	Retained earnings	-	Retained earnings

2. Reasons for the revision

JCR regards the distribution of profits to shareholders as an important management policy. It is the Company’s basic policy to distribute cash dividends on a continued, consistent basis by taking into consideration the business performance and cash flow while securing sufficient internal reserves to develop new drug products that will be a source of future profits and to strengthen financial position of the Company.

In the fiscal year ended March 31, 2024, we have determined to pay a term-end dividend of 10.00 yen per share, as per our more recent dividend forecast.

As a result, the annual dividend for the fiscal year ended March 31, 2024 will be 20.00 yen per share including the interim dividend of 10.00 yen.

3. (Reference) Details of annual dividends

	Dividend per share		
	Interim (End of 2nd quarter)	Year-end	Total
Fiscal year ended March 31, 2024	10.00 yen	10.00 yen	20.00 yen
Actual result for the year ended March 31, 2023	10.00 yen	10.00 yen	20.00 yen

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is redefining expectations and expanding possibilities for people with rare and genetic diseases worldwide. We continue to build upon our 49-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II (Hunter syndrome), MPS III A and B (Sanfilippo syndrome type A and B), and more. JCR strives to expand the possibilities for patients while accelerating medical advancement at a global level. Our core values – reliability, confidence, and persistence – benefit all our stakeholders, including employees, partners, and patients. Together we soar. For more information, please visit <https://www.jcrpharm.co.jp/en/site/en/>.

Cautionary Statement Regarding Forward-Looking Statements

This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such as “believe,” “estimate,” “anticipate,” “intend,” “plan,” “will,” “would,” “target” and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but are not limited to, a deterioration of economic conditions, a change in the legal or governmental system, a delay in launching a new product, impact on competitors' pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights, an adverse court decision in a significant lawsuit and regulatory actions.

This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue.

Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future.

Contact:

Investors & Media:

JCR Pharmaceuticals Co., Ltd.

Corporate Communications

ir-info@jcrpharm.com

###